• Skylight Health Group (SLHG) provided an update on the status of its research program, Skylight Health Research
  • Skylight Health Research has been awarded 11 clinical studies and four are ongoing
  • Total revenue earned through clinical studies in 2021 was $300,000, which has more than doubled in 2022
  • Skylight recently announced two new partnerships with Elligo Health Research and Endominance
  • Skylight Health Group Inc. (SLHG) is up 12.82 per cent trading at C$0.88 per share at 10:05 am ET

Skylight Health Group (SLHG) provided an update on the status of its research program, Skylight Health Research.

Formally launched in 2021, Skylight Health Research has been awarded 11 clinical studies and four are currently ongoing at three clinics. The newest study awarded will be conducted at three clinics launching in September 2022. 

Total revenue earned through clinical studies in 2021 was $300,000, which has more than doubled in 2022 so far.

Skylight recently announced two new partnerships with Elligo Health Research and Endominance.

Skylight Health Research officially joined Elligo’s clinical research network in 2022 and has been working to fully onboard all five clinics participating in Elligo’s Research Ready program.

The Endominance partnership involves their Microbiome, Anxiety, & Cognitive Orientation (MACO) study to assist with patient recruitment. The purpose of the MACO study is to better understand how gut bacteria may affect the brain and how they may be associated with anxious human behaviour and cognitive traits.

Skylight’s VP of Clinical Research, Alisha Garibaldi called this a fitting and seamless partnership.

“The relationship between the microbiome and mental health has become a much more common topic lately, and the MACO study is investigating this complex relationship on a very large scale. We’re excited to work with Endominance on a study that aligns so closely with Skylight’s values and drive to contribute to the advancement of medical science.”

Skylight Health operates a U.S. multi-state primary care health network providing sub-specialty, allied health, and laboratory/diagnostic testing.

Skylight Health Group Inc. (SLHG) is up 12.82 per cent trading at C$0.88 per share at 10:05 am ET.


More From The Market Online

Calian scores $23 million Canadian Armed Forces contract

Calian Group Ltd. (TSX:CGY) has been awarded a $17 million contract by the Canadian Armed Forces’ Canadian Forces Health Services Group.

Unsung profits: Three microcap stocks with a strong case for value

A key factor behind picking winning microcap value stocks is identifying dislocations between company performance and market perception.

This life sciences company is gearing up to treat long COVID  

Revive Therapeutics (CSE:RVV), a Toronto-based company, has immense potential to capitalize on treating long COVID symptoms.

Theralase advances cancer research after private placement

Theralase Technologies (TSXV:TLT) closes a non-brokered private placement offering of 4.1 million shares for gross proceeds of C$750,200.